[go: up one dir, main page]

NO20031741L - Anvendelse av progestiner for induksjon av apoptose i en celle - Google Patents

Anvendelse av progestiner for induksjon av apoptose i en celle

Info

Publication number
NO20031741L
NO20031741L NO20031741A NO20031741A NO20031741L NO 20031741 L NO20031741 L NO 20031741L NO 20031741 A NO20031741 A NO 20031741A NO 20031741 A NO20031741 A NO 20031741A NO 20031741 L NO20031741 L NO 20031741L
Authority
NO
Norway
Prior art keywords
cell
antiprogestin
apoptosis
progestins
induction
Prior art date
Application number
NO20031741A
Other languages
English (en)
Other versions
NO20031741D0 (no
Inventor
Jens Hoffmann
Rosemarie Lichtner
Gerhard Siemeister
Martin Schneider
Ulrike Fuhrmann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20031741D0 publication Critical patent/NO20031741D0/no
Publication of NO20031741L publication Critical patent/NO20031741L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Foreliggende oppfinnelse gjelder fremgangsmåter og anvendelser for induksjon av apoptose i en celle, fortrinnsvis en brystkreftcelle, ved tilførsel av antiprogestiner, fortrinnsvis antiprogestinet 11 P-(4-acetylfenyl)-17P- hydroksy-17a-(l,l,2,2,2-pentafluoretyl)-østra-4,9-dien-3-on eller et farmasøytisk aksepterbart derivat eller en analog derav. Oppfinnelsen gjelder videre behandling av en kreftform hvori en indikator på høy risiko er et forhøyet antall tumorceller i S-fasen i cellesyklus, hvor behandlingen omfatter et antiprogestin, fortrinnsvis antiprogestinet lip-(4-acetylfenyl)-17P- hydroksy-17a-(l,l,2,2,2-pentafluoretyl)- østra-4,9-dien-3-on eller et farmasøytisk aksepterbart derivat eller en analog derav.
NO20031741A 2000-10-18 2003-04-15 Anvendelse av progestiner for induksjon av apoptose i en celle NO20031741L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24099100P 2000-10-18 2000-10-18
EP00250342 2000-10-18
PCT/EP2001/012006 WO2002032432A1 (en) 2000-10-18 2001-10-17 Use of antiprogestins for the induction of apoptosis in a cell

Publications (2)

Publication Number Publication Date
NO20031741D0 NO20031741D0 (no) 2003-04-15
NO20031741L true NO20031741L (no) 2003-06-17

Family

ID=26072952

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031741A NO20031741L (no) 2000-10-18 2003-04-15 Anvendelse av progestiner for induksjon av apoptose i en celle

Country Status (29)

Country Link
EP (1) EP1326617B9 (no)
JP (1) JP2004511523A (no)
KR (1) KR100668024B1 (no)
CN (1) CN1209111C (no)
AT (1) ATE334683T1 (no)
AU (2) AU2002223619B2 (no)
BG (1) BG107744A (no)
BR (1) BR0114696A (no)
CA (1) CA2423020C (no)
CY (1) CY1105745T1 (no)
CZ (1) CZ299823B6 (no)
DE (1) DE60121980T2 (no)
DK (1) DK1326617T3 (no)
EA (1) EA010593B1 (no)
EE (1) EE200300157A (no)
ES (1) ES2269492T3 (no)
HK (1) HK1062273A1 (no)
HR (1) HRP20030388A2 (no)
HU (1) HUP0301433A3 (no)
IL (2) IL154976A0 (no)
MX (1) MXPA03002955A (no)
NO (1) NO20031741L (no)
NZ (1) NZ538347A (no)
PL (1) PL360157A1 (no)
PT (1) PT1326617E (no)
SI (1) SI1326617T1 (no)
SK (1) SK4702003A3 (no)
UA (1) UA76729C2 (no)
WO (1) WO2002032432A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27301A1 (es) * 2001-05-25 2003-02-28 Schering Ag Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la próstata
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
EP2148682A1 (en) * 2007-04-23 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in brca mediated diseases
CA2683809A1 (en) * 2007-04-23 2008-10-30 Bayer Schering Pharma Aktiengesellschaft Progesterone-receptor antagonist for use in brca alone or as combination with antiestrogen
US20080268041A1 (en) * 2007-04-23 2008-10-30 Jens Hoffmann Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
KR102009007B1 (ko) * 2011-10-04 2019-08-08 인비비스 파마슈티컬스 인코포레이티드 항-프로게스틴 민감성 종양을 확인하고 치료하기 위한 방법 및 시스템

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette

Also Published As

Publication number Publication date
UA76729C2 (uk) 2006-09-15
CN1209111C (zh) 2005-07-06
CA2423020C (en) 2009-01-20
SK4702003A3 (en) 2004-01-08
KR20030057540A (ko) 2003-07-04
BG107744A (bg) 2004-02-27
CN1469749A (zh) 2004-01-21
WO2002032432A1 (en) 2002-04-25
HK1062273A1 (en) 2004-10-29
IL154976A (en) 2007-05-15
PT1326617E (pt) 2006-12-29
BR0114696A (pt) 2003-11-18
AU2361902A (en) 2002-04-29
DE60121980D1 (de) 2006-09-14
KR100668024B1 (ko) 2007-01-15
MXPA03002955A (es) 2003-08-07
DK1326617T3 (da) 2006-12-18
EA010593B1 (ru) 2008-10-30
NZ538347A (en) 2007-03-30
CA2423020A1 (en) 2002-04-25
JP2004511523A (ja) 2004-04-15
HUP0301433A2 (hu) 2003-10-28
AU2002223619B2 (en) 2006-08-24
NO20031741D0 (no) 2003-04-15
EA200300479A1 (ru) 2003-10-30
ATE334683T1 (de) 2006-08-15
HUP0301433A3 (en) 2010-01-28
CZ299823B6 (cs) 2008-12-03
CY1105745T1 (el) 2010-12-22
IL154976A0 (en) 2003-10-31
EP1326617A1 (en) 2003-07-16
DE60121980T2 (de) 2007-03-01
ES2269492T3 (es) 2007-04-01
EP1326617B9 (en) 2006-10-25
SI1326617T1 (sl) 2007-02-28
EP1326617B1 (en) 2006-08-02
PL360157A1 (en) 2004-09-06
HRP20030388A2 (en) 2005-04-30
EE200300157A (et) 2003-08-15

Similar Documents

Publication Publication Date Title
CY1104981T1 (el) Χρηση των αντιπρογεστερονων για προληψη και αντιμετωπιση των εξαρτωμενων απο ορμονες ασθενειων
NO986104D0 (no) Progesteron-anti-progesteron regimer
CY1105745T1 (el) Χρηση της 11βητα-(4-ακετυλφαινυλ)-17βητα-υδροξυ-17αλφα(1,1,2,2-πενταφθοροαιθυλ)οιστρα-4,9-διεν-3-ονη για την παρασκευη ενος φαρμακου για την θεραπεια του καρκινου του μαστου, των ωοθηκων και του ενδομητριου, του μυελωματος και του μηνιγγιωματος
ATE270554T1 (de) Kombination der progesteron und mifepristone für krebs-therapie
YU29903A (sh) Upotreba antiprogestina za indukciju apoptoze u ćeliji
JP2004511523A5 (no)
TW200731977A (en) Use of estradiol valerate in combination with dienogest for the oral treatment of dysfunctional uterine bleeding in conjunction with oral contraception
TW200733955A (en) Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
EA200300480A1 (ru) Применение антипрогестинов для профилактики и лечения гормонозависимых заболеваний
DE4494826D2 (de) Oral estrogen wirksame Ester des 14alpha,15alpha-Methylen-estradiols

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application